Kinaxis gets thumbs up from Laurentian Bank for Novartis win

A big customer win for Kinaxis (Kinaxis Stock Quote, Chart TSX:KXS) has earned praise from Laurentian Bank Securities analyst Nick Agostino.

This morning, Kinaxis announced that Swiss pharma giant Novartis had chosen Kinaxis’s RapidResponse as its new supply chain planning system.

“Novartis products reach nearly one billion people globally every year through a supply chain that includes thousands of suppliers and extends into most countries,” the company said in a press release today. “Using Kinaxis, Novartis aims to gain end-to-end supply chain visibility, respond more quickly to changing market demands, improve inventory management and drive down costs. Once fully implemented, Kinaxis will help Novartis drive planning standardization across all divisions of the organization and use advanced analytics to help manage the complexity of business planning.”

Agostino says this sale was a long time in the making and could lead to more business.

“From our conversations with Novartis at KXS’s User Conference in October 2018, the company required the ability to track drug expiration within its Supply Chain, and ultimately focused on KXS as its supplier given it was the only solution in the marketplace capable of meeting Novartis’ requirements,” the analyst explains. “We note Novartis is primarily an SAP firm and had been in dialogue with KXS for well over 1 year. We add Novartis was one of 16 prospects at the 2018 User Conference. The win not only adds to KXS’s penetration within SAP’s client base, but adds to its European presence and helps justify ongoing efforts by KXS within the last 15 months to bolster its sales presence and build out a data centre within that region. The Novartis win also demonstrates the ongoing demand, as reported by KXS, within the Life Sciences market (largest revenue contributor for KXS at ~30%).”

In a research “Flash” update to clients today, Agostino maintained his “Buy” rating and one-year price target of $100.00 on Kinaxis, implying a return of 39.4 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: kxs
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Chorus Aviation price target trimmed at CIBC

Following first quarter results, CIBC analyst Kevin Chiang has lowered his price target on Chorus Aviation (Chorus Aviation Stock Quote,… [Read More]

8 hours ago

Is Magellan Aerospace stock a buy?

Its first quarter results are in the books and Paradigm Capital analyst J Marvin Wolff thinks there is money to… [Read More]

1 day ago

Phunware is undervalued, Roth says

Ahead of the company's first quarter results, Roth MKM analyst Darren Aftahi thinks there is money to be made on… [Read More]

1 day ago

Héroux-Devtek is a buy, Desjardins says

Ahead of the company's quarterly results, Desjardins Securities analyst Benoit Poirier likes what he sees from Héroux-Devtek (Héroux-Devtek Stock Quote,… [Read More]

1 day ago

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

2 days ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

2 days ago